You are here
Generic Actos Receives Approval
November 9, 2004
PITTSBURGH, Nov. 9 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL - News) today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Pioglitazone Hydrochloride Tablets, 15 mg, 30 mg, and 45 mg.
Pioglitazone Hydrochloride Tablets are the generic version of Takeda Pharmaceuticals' Actos® Tablets.
For more information about Mylan, visit www.mylan.com .
Source: Mylan Laboratories Inc.
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs